Some treatments show potential for wider application.
GlobalData said biologic therapies could help advance the treatment of severe asthma by targeting specific inflammatory pathways, shifting care from symptom control to potential relief.
The biologic treatment, initially focused on eosinophilic asthma, now has the potential for broader application, bringing benefits to patients with a variety of inflammatory profiles, GlobalData said in a statement.
“Biologics are fundamentally changing the way we treat severe asthma by enabling targeted, personalized treatments, but expanded access is critical to realizing their full potential,” said Sravani Meka, senior pharmaceutical analyst at GlobalData.
“The long-term effects of these therapies may shift asthma treatment from simply controlling symptoms to achieving remission, similar to advances in areas such as rheumatoid arthritis,” Meka added.
However, cost, access, and insurance barriers limit the availability of biologic therapies, especially in underserved communities. Environmental and social factors also complicate asthma treatment, as many patients in high-risk areas are exposed to pollutants that can worsen symptoms.
While efforts are underway to expand the use of biologics in the treatment of severe asthma, experts say success still depends on systemic changes that improve equity and accessibility in health care.
“To truly transform asthma care, ongoing attention to cost and access issues is needed to ensure that biologics are available to all patients who could benefit from them,” Meka said.
